Orthofix Medical (NASDAQ:OFIX) Earns "Outperform" Rating from Barrington Research

Orthofix Medical (NASDAQ:OFIX - Get Free Report)'s stock had its "outperform" rating restated by Barrington Research in a research note issued on Thursday,Benzinga reports. They currently have a $17.00 price objective on the medical device company's stock. Barrington Research's target price would indicate a potential upside of 4.74% from the stock's previous close.

Several other equities analysts have also recently weighed in on OFIX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a report on Wednesday, October 8th. Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.

Orthofix Medical Price Performance

Shares of OFIX stock opened at $16.23 on Thursday. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38. Orthofix Medical has a 12 month low of $10.24 and a 12 month high of $20.73. The firm has a market cap of $640.92 million, a price-to-earnings ratio of -5.12 and a beta of 0.89. The stock has a 50-day moving average price of $14.70 and a 200 day moving average price of $12.91.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The company had revenue of $203.12 million for the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Research analysts expect that Orthofix Medical will post -2.81 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Orthofix Medical during the 1st quarter worth approximately $575,000. Gradient Capital Advisors LLC acquired a new position in Orthofix Medical in the 2nd quarter valued at $223,000. Philosophy Capital Management LLC acquired a new position in Orthofix Medical in the 1st quarter valued at $6,047,000. American Century Companies Inc. grew its holdings in Orthofix Medical by 10.0% in the 1st quarter. American Century Companies Inc. now owns 79,652 shares of the medical device company's stock valued at $1,299,000 after buying an additional 7,230 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in Orthofix Medical by 161.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 78,220 shares of the medical device company's stock valued at $1,276,000 after buying an additional 48,353 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.